Relafen 750, chemically known as naproxen, represents a noteworthy case study from a pharmacological pharmacy standpoint. It's exhibits its therapeutic effect primarily by inhibiting the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby decreasing prostaglandin synthesis . The targeted inhibition of COX-2, compared to traditiona